Trial record 1 of 6 for:    ELND005
Previous Study | Return to List | Next Study

A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

This study is enrolling participants by invitation only.
Sponsor:
Collaborator:
Elan Pharmaceuticals
Information provided by (Responsible Party):
Elan Pharmaceuticals ( Elan Pharma International Limited )
ClinicalTrials.gov Identifier:
NCT01766336
First received: January 8, 2013
Last updated: July 3, 2014
Last verified: July 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is enrolling participants by invitation only.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: February 2016 (Final data collection date for primary outcome measure)